Sacroiliac Joint Fusion Market

About 1,770 US physicians performed a procedure with SI-BONE’s iFuse implants in the third quarter of 2026, up about 16%, and US procedure volume rose about 19.5%, its results of 2 November 2026 show, while worldwide revenue grew 14.5% to USD 55.7 million. The sacroiliac joint fusion market covers the implants and single-use procedure kits used to fuse or fix the joint between the sacrum and the ilium: lateral transiliac devices, posterior and posterolateral intra-articular implants, sacroiliac fixation in spinopelvic fusion constructs, and pelvic trauma fixation across the joint. Douglas Insights sizes it at USD 420 million in 2025, about 82,000 procedures at an average USD 5,120 of implant revenue each, and at USD 899 million in 2035, a 7.91% compound annual growth rate (CAGR). The study sits beside our Medical Implants Market, Pain Management Devices Market and U.S. Surgical Robotics Market reports; every figure follows the Douglas Insights research methodology.

Which sacroiliac joint fusion approach earns the most: lateral transiliac, posterior, spinopelvic or pelvic trauma?

Lateral transiliac implants earn the most, 52.0% of 2025 sacroiliac joint fusion value or about USD 218 million, Douglas Insights estimates. Posterior intra-articular implants grow fastest, 10.2% a year to USD 244 million by 2035.

Lateral transiliac implants lead because they were the first minimally invasive designs with long-term trial data and because CPT 27279, the code for devices that pierce the cortices of the ilium and sacrum, carries the highest physician work value of the two fusion codes: 11.83 work units against 7.66 for 27278, per the 2026 CPT update summarised by ISASS. SI-BONE’s triangular titanium iFuse family, Medtronic’s Rialto and Globus Medical’s SI-LOK are the main lateral systems. Douglas Insights estimates about 42,600 lateral procedures in 2025 at an average USD 5,120; their value grows 6.8% a year to USD 422 million.

Posterior and posterolateral implants, USD 92.4 million, grow fastest at 10.2% because pain physicians can place them through a small incision in an ambulatory surgery centre (ASC). Tenon Medical’s Catamaran, PainTEQ’s LinQ and TRAQ and Aurora Spine’s SiLO TFX sit here. Spinopelvic fixation, USD 67.2 million, grows 9.6% as deformity surgeons anchor long fusions across the joint with devices such as iFuse Bedrock Granite. Pelvic trauma fixation, USD 42.0 million, grows 6.6%. Approach values for 2035 sum to USD 913 million, 1.57% above the headline.

Where are sacroiliac joint fusion procedures performed: hospital outpatient, inpatient or ambulatory surgery centres?

Hospital outpatient departments take the most, 46.0% of 2025 value or about USD 193 million, Douglas Insights estimates. Ambulatory surgery centres grow fastest, 9.6% a year from USD 92.4 million to USD 231 million by 2035.

Hospital outpatient departments lead because Medicare pays the facility a national unadjusted USD 17,914 for either fusion code under comprehensive APC 5116, SI-BONE’s CY2026 facility coding guide shows. The inpatient setting, USD 134 million, holds deformity and trauma cases: the same guide lists FY2026 payments of USD 38,782 under MS-DRG 450 and USD 23,507 under MS-DRG 451 for percutaneous sacroiliac fusion. Inpatient value grows 7.4% a year to USD 274 million, a Douglas Insights estimate.

Ambulatory surgery centres, USD 92.4 million, grow fastest at 9.6%. Medicare pays an ASC USD 14,518 for 27279 and USD 15,048 for 27278, both flagged as device-intensive, per the February 2026 guide, and SI-BONE launched its INTRA Ti implant for ASCs in February 2026, its results of 23 February 2026 state. Site values for 2035 sum to USD 907 million, 0.91% above the headline.

What drives sacroiliac joint fusion demand: surgeon adoption, spinopelvic fixation, ASC migration or new posterior devices?

Procedures rise 9.0% a year in our base case, from about 82,000 in 2025 to about 194,000 in 2035. Four drivers add 11.0 points of gross growth; three restraints remove 2.0 points.

Surgeon adoption and diagnosis of sacroiliac pain: 4.50 points

Adoption is the largest driver, worth 4.50 points. About 1,640 US physicians performed an SI-BONE procedure in the fourth quarter of 2025, up 18%, and full-year 2025 revenue rose 20.2% to USD 200.9 million, US revenue 20.6% to USD 191.1 million, its results of 23 February 2026 show. By the third quarter of 2026 the count reached 1,770, up about 16%, and procedures grew about 19.5%, per its 2 November 2026 results. Douglas Insights estimates that only about 1 in 6 US spine and pain specialists who see sacroiliac pain performed a fusion in 2025, so the trained pool can keep growing at 10% to 12% a year.

Spinopelvic fixation and new inpatient payment: 2.50 points

Deformity surgery adds 2.50 points. SI-BONE received 510(k) clearance in September 2026 for iFuse Granite Onyx, an FDA breakthrough device aimed at failed spine fusions with an estimated total addressable market of about USD 1.5 billion a year, and new MS-DRGs for complex spinal fusion took effect in October 2026, raising average inpatient payments by up to about USD 50,000 per qualifying procedure, its Q3 2026 release states. Douglas Insights estimates that about 13,000 long-construct fusions in 2025 used a dedicated sacroiliac fixation implant, about 16% of procedures, rising to about 21% by 2035.

Migration to ambulatory surgery centres: 2.20 points

ASC migration adds 2.20 points. Medicare’s ASC rates of USD 14,518 for 27279 and USD 15,048 for 27278 are 81% to 84% of the USD 17,914 outpatient rate, the CY2026 coding guide shows, a margin that lets pain physicians and spine surgeons move cases out of hospitals. The CY2027 outpatient rule removes 637 more services from the inpatient-only list, its fact sheet states, widening the set of spine cases ASCs can take. Douglas Insights estimates that ASCs did about 24% of US sacroiliac fusions in 2025 and will do about 33% by 2035.

New posterior devices and navigation: 1.80 points

New devices add the last 1.80 points. The FDA cleared Tenon Medical’s Catamaran SI Joint Fusion System under 510(k) K260477 on 8 April 2026, product code OUR, the FDA 510(k) database shows, and Tenon’s second-quarter 2026 revenue rose 127% to USD 1.3 million, its results of 13 August 2026 show. PainTEQ launched its TRAQ bicortical implant in the US beside LinQ, Hospital Management reported on 18 May 2026, and SurGenTec added Medtronic StealthStation navigation to its TiLink system, its release of 15 April 2026 states. Summed, 4.50 + 2.50 + 2.20 + 1.80 = 11.0 points, a Douglas Insights estimate.

What holds sacroiliac joint fusion back: Medicare coverage criteria, coding limits or crowded pain clinics?

Three restraints remove 2.0 points a year from procedure growth: Medicare coverage criteria take 0.90 points, coding and physician payment limits 0.60 points and crowding in the pain-clinic segment 0.50 points.

Coverage criteria are the heaviest drag. Noridian’s final local coverage determination L39810, Minimally Invasive Arthrodesis of the Sacroiliac Joint, took effect on 16 February 2025 for Jurisdiction E, its notice of 2 January 2025 states, one of a set of matching policies from several Medicare contractors that list the indications and medical-necessity documentation each claim needs. Douglas Insights estimates that documentation and prior-authorisation steps defer about 1 in 10 otherwise eligible Medicare and commercial cases each year.

Coding and physician payment take 0.60 points. From 2026, 27278 covers only intra-articular devices that do not pierce the cortices, and hybrid constructs with a cortex-piercing device must be billed as 27279, the ISASS summary shows, which narrows the lower-work code that many pain physicians use. The CY2027 physician fee schedule cuts the conversion factor 2.31% to USD 32.63, its fact sheet of 4 November 2026 states. Crowding takes the last 0.50 points: Aurora Spine’s second-quarter 2026 revenue fell 18.7% to USD 3.66 million on lower sales of sacroiliac joint products, its release of 27 August 2026 states, citing increased competition.

Which region buys the most sacroiliac joint fusion implants, and where does demand grow fastest?

North America buys the most sacroiliac joint fusion implants, USD 353 million or 84.0% of 2025 value, and Asia Pacific grows fastest, 9.8% a year from USD 16.8 million to USD 42.8 million by 2035.

North America leads because US coding, Medicare coverage policies and a large network of spine surgeons and interventional pain physicians make the procedure routine. SI-BONE earned USD 52.8 million in the US and only USD 2.9 million internationally in the third quarter of 2026, a 95% US share, per its 2 November 2026 results. Regional value grows 7.8% a year to USD 747 million, a Douglas Insights estimate.

Europe, USD 42.0 million, grows 8.4%: SI-BONE’s international revenue rose 27.0% in the third quarter of 2026 from a small base, and German, Italian and UK spine centres account for most European cases, Douglas Insights estimates. Asia Pacific, USD 16.8 million, grows fastest at 9.8% from a very low procedure base in Australia, Japan and Korea. Latin America, USD 5.0 million, and the Middle East and Africa, USD 3.4 million, each grow 8.6%. Regional values sum to USD 453 million in 2026, 0.04% above the headline, and USD 903 million in 2035, 0.50% above it.

Which companies lead the sacroiliac joint fusion market?

SI-BONE leads sacroiliac joint fusion with about 48% of 2025 value, Douglas Insights estimates, ahead of Medtronic at about 12%, Globus Medical at about 9%, PainTEQ at about 6% and Aurora Spine at about 2%.

SI-BONE is the only listed pure-play: it guides 2026 revenue of USD 231 million to USD 233 million, growth of about 15% to 16%, with gross margin of about 79.0% and positive adjusted EBITDA, its Q3 2026 release shows, and it partners with Smith+Nephew to sell iFuse TORQ and TORQ TNT into Level 1 and Level 2 trauma centres, per its February 2026 results. Its US patent on the original triangular iFuse runs to August 2028, the same release states, which opens the lateral segment to copies from 2029.

Medtronic and Globus Medical sell sacroiliac systems inside broad spine portfolios, so their sacroiliac revenue is not disclosed; our shares for them are Douglas Insights estimates built from surgeon-survey mix and spine sales. Aurora Spine grew 2025 revenue 4.6% to USD 18.4 million on Zip implants and sacroiliac fusion devices, Becker’s Spine Review reported on 30 April 2026, then signed a royalty agreement settling its SiLO TFX patent arbitration and a commercial alliance with CornerLoc, per its 27 August 2026 release.

The posterior segment is crowded with small private makers: CornerLoc, SurGenTec, Camber Spine and others share the remaining 23% of value, a Douglas Insights estimate. Tenon Medical’s first-quarter 2026 revenue rose about 90% to USD 1.38 million with gross margin of 68.5%, its results of 12 May 2026 show, yet it held only USD 1.68 million of cash at 30 June 2026, per its second-quarter release. Douglas Insights expects at least two posterior makers to merge or be acquired before 2030.

How much does sacroiliac joint fusion cost, from a posterior allograft kit to a spinopelvic construct?

A sacroiliac joint fusion procedure brings an average USD 5,120 of implant revenue in 2025, Douglas Insights estimates, from about USD 2,500 for a posterior allograft kit to about USD 9,000 for a spinopelvic fixation set.

The price ladder follows implant count and material. A lateral procedure with three titanium implants sells for about USD 4,500 to USD 6,500, a posterior intra-articular implant with graft for about USD 2,500 to USD 4,500, a spinopelvic fixation set of two to four implants for USD 6,000 to USD 9,000 and a pelvic trauma construct for USD 3,000 to USD 6,000, Douglas Insights estimates. Device cost drives facility margins: Medicare treats 66.00% of the ASC rate for 27279 and 72.65% of the rate for 27278 as device cost, the CY2026 coding guide shows, roughly USD 9,600 and USD 10,900.

Average implant revenue per procedure falls 1.0% a year in the base case, to about USD 4,630 in 2035, because posterior and ASC cases gain share and lateral prices fall after the 2028 patent expiry. SI-BONE’s US revenue grew 13.9% in the third quarter of 2026 while procedures grew about 19.5%, per its results, which implies US revenue per procedure fell about 4.7%, a Douglas Insights calculation. One spinopelvic set is worth about three posterior kits, a Douglas Insights estimate.

What if coverage tightens or adoption accelerates: how large is the market in 2035?

The sacroiliac joint fusion market ends 2035 between USD 644 million and USD 1.22 billion across our three cases, around a base of USD 899 million. Medicare coverage and the pace of surgeon training set most of the spread.

In the slower case more Medicare contractors and commercial payers narrow covered indications, posterior devices lose coverage and generic lateral implants arrive in 2029, taking 2.5 points off procedures and 1.0 point off price. In the faster case spinopelvic fixation becomes standard in long fusions, ASCs take most outpatient cases and Europe adopts US-style coding, adding 2.5 points of procedures and 0.8 points of price. One extra point of yearly revenue growth adds about USD 85 million to 2035 value, a Douglas Insights estimate.

Live signals sit near the base case. SI-BONE’s 19.5% procedure growth and 16% physician growth point up; Aurora Spine’s 18.7% revenue fall and SI-BONE’s falling revenue per procedure point down. The signal to watch is SI-BONE’s fourth quarter of 2026: if Granite Onyx alpha cases convert into a full launch, Douglas Insights would raise spinopelvic growth by about 1 point.

Which rules shape sacroiliac joint fusion, from FDA product code OUR to EU MDR deadlines?

Three rule sets shape sacroiliac joint fusion: FDA 510(k) review under product code OUR in the US, CPT coding and Medicare coverage policies, and the EU Medical Device Regulation with its transition deadlines.

The clearance layer is open to new entrants. The FDA reviews sacroiliac fusion implants as Class II devices under 21 CFR 888.3040, product code OUR; Tenon’s K260477 was received on 17 February 2026 and cleared on 8 April 2026, the FDA database shows, under two months. Breakthrough designation speeds harder indications: iFuse Granite Onyx, for failed spine fusions, was cleared in September 2026 as a breakthrough device, SI-BONE’s release states.

The payment layer decides volume. The 2026 CPT revision ties 27279 to devices that pierce the ilium and sacrum and 27278 to intra-articular devices that do not, with total facility values of 23.21 and 13.19 units, the ISASS summary shows, and local coverage determinations such as L39810 set clinical criteria, per Noridian. In Europe, Regulation (EU) 2023/607 extends MDR transition to 31 December 2027 for class III and implantable class IIb devices, the EUR-Lex text shows; most sacroiliac implants fall in that group, so small makers face recertification costs before 2028, a Douglas Insights estimate.

Douglas Exclusive: the Procedure-Price Squeeze

The Procedure-Price Squeeze is a Douglas Insights model of 9 inputs: 7 company records and 2 payment records, listed below. It compares procedure growth with revenue growth to show how fast implant revenue per procedure is falling as cases move to cheaper settings and devices.

The finding, a Douglas Insights estimate: the market leader’s US revenue per procedure fell about 4.7% in the third quarter of 2026 (1.139 / 1.195 = 0.953), while its active physicians grew about 16%. New physicians start with simpler cases, more cases move to ASCs where the facility payment is 16% to 19% lower, and posterior entrants such as Tenon and PainTEQ add low-price competition, the same pressure that cut Aurora Spine’s sales.

The squeeze changes how to read headline revenue. Implant makers growing revenue at 14% to 15% are growing procedures nearer 20%, so the clinical base is expanding faster than sales suggest. If the squeeze persists at 3% to 5% a year, it would offset spinopelvic price gains and hold our base-case price leg at about minus 1.0% a year, rather than the flat price many vendors assume.

How does the methodology turn 82,000 procedures into USD 420 million?

Our methodology multiplies about 82,000 sacroiliac joint fusion procedures in 2025 by an average USD 5,120 of implant revenue each to reach USD 420 million, then grows procedures 9.0% a year and revenue per procedure minus 1.0% a year.

The model covers 4 approaches, 3 sites of care and 5 regions, using 52 data points, 21 sourced and 31 modelled. Procedures come from a build of about 69,000 in North America, 8,200 in Europe, 3,300 in Asia Pacific and 1,500 elsewhere, Douglas Insights estimates drawn from company disclosures, Medicare coding and surgeon counts. Arithmetic: 82,000 x USD 5,120 = USD 420 million; USD 420 million x (1.090 x 0.990)^10 = USD 899 million. Procedures reach about 89,400 in 2026 and 194,000 in 2035.

Two cross-checks agree. First, our 48% SI-BONE share equals about USD 201 million, matching its USD 200.9 million 2025 revenue. Second, about 1,640 active US physicians averaging about 24 procedures a year gives about 39,400 SI-BONE cases, matching the 39,200 implied by its 2025 revenue at our average USD 5,120, a Douglas Insights cross-check. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our editorial standards explain.

Sources

1. SI-BONE SI-BONE Q3 2026 results (2026)
2. SI-BONE SI-BONE Q4 and FY2025 results (2026)
3. US Food and Drug Administration FDA 510(k) K260477 Catamaran SI Joint Fusion System (2026)
4. Tenon Medical Tenon Medical Q2 2026 results (2026)
5. Aurora Spine Aurora Spine Q2 FY26 results (2026)
6. SI-BONE SI Joint Dysfunction Facility 2026 Coding Guide (2026)
7. ISASS 2026 CPT code updates for spine surgery (2026)
8. Noridian LCD L39810 Minimally Invasive Arthrodesis of the SIJ (2025)
9. CMS CY2027 Medicare Physician Fee Schedule final rule (2026)
10. EUR-Lex Regulation (EU) 2023/607 (2023)

What counts in the sacroiliac joint fusion study, and what is excluded?

The sacroiliac joint fusion study counts lateral transiliac implants, posterior and posterolateral intra-articular implants, sacroiliac fixation implants in spinopelvic constructs, pelvic trauma fixation across the joint, and their single-use instruments. Radiofrequency ablation, injections, navigation hardware and bone graft sold separately are excluded.

The study splits value by 4 approaches, 3 sites of care and 5 regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Broader implantable devices appear in our Medical Implants Market report, non-surgical options in the Pain Management Devices Market study and navigation and robotic platforms in the U.S. Surgical Robotics Market report.